ofloxacin has been researched along with Soft Tissue Infections in 9 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Soft Tissue Infections: Infections of non-skeletal tissue, i.e., exclusive of bone, ligaments, cartilage, and fibrous tissue. The concept is usually referred to as skin and soft tissue infections and usually subcutaneous and muscle tissue are involved. The predisposing factors in anaerobic infections are trauma, ischemia, and surgery. The organisms often derive from the fecal or oral flora, particularly in wounds associated with intestinal surgery, decubitus ulcer, and human bites. (From Cecil Textbook of Medicine, 19th ed, p1688)
| Excerpt | Relevance | Reference |
|---|---|---|
| "This was a double-blind, multicenter study in which 410 adults (> or =18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days." | 9.09 | Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. ( Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ, 2001) |
| " To this day, no other case of prostatic abscess due to this strain but susceptible to methicillin has been described." | 7.80 | Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. ( Barraud, O; Brakbi, Y; Cypierre, A; Dubos, M; Fedou, AL; François, B; Fredon, F; Laurent, F, 2014) |
| "The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method." | 7.70 | In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. ( Finegold, SM; Molitoris, D; Molitoris, E; Wexler, HM, 1998) |
| "Levofloxacin was assayed by high-performance liquid chromatography." | 5.32 | Tissue pharmacokinetics of levofloxacin in human soft tissue infections. ( Bellmann, R; Dehghanyar, P; Joukhadar, C; Kuchling, G; Mayer, BX; Minar, E; Müller, M; Zeitlinger, M, 2004) |
| "This was a double-blind, multicenter study in which 410 adults (> or =18 years of age) with uncomplicated skin and soft tissue infections (SSTIs) were randomized to receive either 400 mg of gatifloxacin orally once daily or 500 mg of levofloxacin orally once daily for 7 to 10 days." | 5.09 | Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. ( Breen, JD; Brown, MJ; Champlin, J; Jones, TM; Miskin, BM; Tarshis, GA; Wingert, KJ, 2001) |
| " To this day, no other case of prostatic abscess due to this strain but susceptible to methicillin has been described." | 3.80 | Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. ( Barraud, O; Brakbi, Y; Cypierre, A; Dubos, M; Fedou, AL; François, B; Fredon, F; Laurent, F, 2014) |
| "The in vitro activity of levofloxacin was compared to the activities of ofloxacin, ciprofloxacin, ampicillin-sulbactam (2:1), cefoxitin, and metronidazole for a selected group of anaerobes (n = 175) isolated from skin and soft tissue infections by using the National Committee for Clinical Laboratory Standards-approved Wadsworth method." | 3.70 | In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections. ( Finegold, SM; Molitoris, D; Molitoris, E; Wexler, HM, 1998) |
| "Oral levofloxacin was also similar in efficacy to amoxicillin/clavulanic acid or oral clarithromycin in patients with acute maxillary sinusitis treated for 7 to 14 days." | 2.40 | Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract. ( Lamb, HM; Langtry, HD, 1998) |
| "Levofloxacin was assayed by high-performance liquid chromatography." | 1.32 | Tissue pharmacokinetics of levofloxacin in human soft tissue infections. ( Bellmann, R; Dehghanyar, P; Joukhadar, C; Kuchling, G; Mayer, BX; Minar, E; Müller, M; Zeitlinger, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dubos, M | 1 |
| Barraud, O | 1 |
| Fedou, AL | 1 |
| Fredon, F | 1 |
| Laurent, F | 1 |
| Brakbi, Y | 1 |
| Cypierre, A | 1 |
| François, B | 1 |
| Blatun, LA | 2 |
| Terekhova, RP | 1 |
| Kouame, K | 1 |
| Ecra, E | 1 |
| Cisse, M | 1 |
| Gbery, I | 1 |
| Kacou, E | 1 |
| Kassi, K | 1 |
| Kouassi, A | 1 |
| Ahogo, C | 1 |
| Yoboue, P | 1 |
| Kanga, JM | 1 |
| Bellmann, R | 1 |
| Kuchling, G | 1 |
| Dehghanyar, P | 1 |
| Zeitlinger, M | 1 |
| Minar, E | 1 |
| Mayer, BX | 1 |
| Müller, M | 1 |
| Joukhadar, C | 1 |
| Iakovlev, VP | 1 |
| Svetukhin, AM | 1 |
| Ukhin, SA | 1 |
| Liu, HH | 1 |
| Bolash, NK | 1 |
| McAnany, ME | 1 |
| Lynch, RA | 1 |
| Wexler, HM | 1 |
| Molitoris, E | 1 |
| Molitoris, D | 1 |
| Finegold, SM | 1 |
| Langtry, HD | 1 |
| Lamb, HM | 1 |
| Tarshis, GA | 1 |
| Miskin, BM | 1 |
| Jones, TM | 1 |
| Champlin, J | 1 |
| Wingert, KJ | 1 |
| Breen, JD | 1 |
| Brown, MJ | 1 |
3 reviews available for ofloxacin and Soft Tissue Infections
| Article | Year |
|---|---|
[Levofloxacin in complex therapy of patients with skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Humans; Levofloxacin; Ofloxacin; Skin Diseases, Bacterial; Soft Tissue Infect | 2008 |
[Modern fluoroquinolones (ciprofoxacin, levofloxacin) and the treatment of skin and soft tissue infections].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Central Nervous System Diseases; Ciprofloxacin; Gastro | 2004 |
Levofloxacin. Its use in infections of the respiratory tract, skin, soft tissues and urinary tract.
Topics: Animals; Anti-Infective Agents; Humans; Levofloxacin; Ofloxacin; Respiratory Tract Infections; Skin | 1998 |
2 trials available for ofloxacin and Soft Tissue Infections
| Article | Year |
|---|---|
Susceptibility of bacterial isolates from complicated skin and skin structure infections to cefazolin, imipenem-cilastatin, ciprofloxacin and ofloxacin.
Topics: Adolescent; Adult; Anti-Infective Agents; Bacteria; Cefazolin; Cilastatin; Cilastatin, Imipenem Drug | 1995 |
Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Infective Agents; Double-Blind Method; Drug Admi | 2001 |
4 other studies available for ofloxacin and Soft Tissue Infections
| Article | Year |
|---|---|
Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin.
Topics: Abscess; Bacterial Toxins; Exotoxins; Humans; Leukocidins; Magnetic Resonance Imaging; Male; Methici | 2014 |
[Buruli ulcer involving the head: outcomes and therapeutic aspects in 8 cases observed at the University Hospital Center in Abidjan, Cote d'Ivoire].
Topics: Adolescent; Anti-Bacterial Agents; Anticoagulants; Buruli Ulcer; Child; Child, Preschool; Cote d'Ivo | 2008 |
Tissue pharmacokinetics of levofloxacin in human soft tissue infections.
Topics: Adipose Tissue; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Chromatography, High Pressure | 2004 |
In vitro activity of levofloxacin against a selected group of anaerobic bacteria isolated from skin and soft tissue infections.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Colony Count, Microbial; Humans; Levofloxacin; Microbial | 1998 |